ADA 2026 GLP-1 Pipeline: Retatrutide, CagriSema, Orforglipron The next wave of incretin therapies unveiled in New Orleans. (2026). Diabzen, 4(23), 46-47. https://thediabzen.com/index.php/d/article/view/66